



**Webinar | IMI2 - Call 23**

**Turkey in Horizon 2020 Phase II**

**Polyvios HADJIYAINGOU**  
IMI2 JU Scientific Operations Coordinator

# Outline

1. Introducing IMI
2. Participation rules
3. Funding rules
4. Intellectual property rules
5. From Call to grant award
6. Writing a successful proposal



# Introducing IMI

# IMI – Europe’s partnership for health

## IMI mission

IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

- Non-competitive collaborative research
- Competitive Calls for proposals



# IMI2 budget (2014 – 2020)

## EU funding goes to:

Universities  
SMEs  
Mid-sized companies  
Patient groups  
etc...



€1.638 bn



€1.425 bn

Other  
€213 m

IMI 2 total budget  
€3.276 billion

## EFPIA companies

receive no funding

contribute to projects 'in kind'

Associated Partners e.g. charities, non-EFPIA companies

# IMI2 Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines



The right prevention and treatment  
for the right patient at the right time

Strategic Research Agenda for  
Innovative Medicines Initiative 2

**Aligned with  
WHO priorities**

# IMI life cycle

- **Call topics definition**
  - Scientific Research Agenda
  - Strategic Governing Groups
  - Annual Work Plan
  - Consultation Member-Associated States/Scientific Committee
- **Call Launch / Evaluation / Grant award**
- **Project implementation**

Consortium agreement, Grant agreement, implementation and reporting


# What does the typical IMI project look like?

Industrial partners align themselves around a real challenge for industry and agree to work together and commit resources


New ideas from public sector, universities, SMEs etc. are needed to address the challenge

Scale is a key to success and is provided by IMI funding and the outcomes should be transformative for the industry as well as having a clear “public” value

# A typical IMI consortium



# An international, cross-sector community



# Why applying to IMI2 JU Call for proposals?

- Allow engagement in a cross-sector, multi-disciplinary consortium at the forefront of cutting-edge research
- Provide the necessary scale by combining funding, expertise, knowledge, skills and resources
- Build a trustful collaboration based on creativity and innovative and critical thinking
- Learn from each other - new knowledge, skills, ways of working
- Take part in transformative research that will make a difference in drug development and ultimately patients' lives

IMI - ecosystem for innovative collaborations on **shared challenges.**



# Introduction to IMI2 JU – Call 23

# IMI2 JU Call 23 - topics

- **Topic 1: Returning Clinical Trial Data to Study Participants within a GDPR compliant and approved ethical framework**
- **Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance**
- **Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases**
- **Topic 4: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence**
- **Topic 5: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies**
- **Topic 6: Behavioural Model of Factors Affecting Patient Adherence**

# IMI2 JU Call 23 - topics

<https://www.imi.europa.eu/news-events/events/imi2-call-22-23->

## webinars

### Topic-specific webinars for IMI2 – Call 23

Behavioural Model of Factors Affecting Patient Adherence

Wednesday 17 June | 15:00

Download the [presentation](#)  | Watch the [recording](#) | Download the [list of participants](#) 

Returning re-usable Clinical Trial Data to Study Participants within a GDPR compliant and approved framework

Friday 19 June | 15:00

Download the [presentation](#)  | Watch the [recording](#) | Download the [list of participants](#) 

Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance

Monday 22 June | 11:00

Download the [presentation](#)  | Watch the [recording](#) | Download the [list of participants](#) 

Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence

Thursday 25 June | 15:00

Download the [presentation](#)  | Watch the [recording](#) | Download the [list of participants](#) 

A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases

Friday 26 June | 15:30

Download the [presentation](#)  | Watch the [recording](#) | Download the [list of participants](#) 

Shortening the path to Rare Disease diagnosis by using new born genetic screening and digital technologies

Monday 29 June | 15:00

Download the [presentation](#)  | Watch the [recording](#) | Download the [list of participants](#) 

# IMI 2 JU - Call 23 two stages

- Date of Call launch: 23 June 2020
- Calls text and documents are published on the:  
IMI2 JU website and the Funding and Tenders Portal
- **Deadline for Short Proposal submission:** 29 September 2020  
(17:00:00 Brussels time)
- **Deadline for Full Proposal submission:** 17 March 2021 (17:00:00  
Brussels time)

# Call 23 – two stages

- At stage 1 evaluation the **budget** is evaluated under criterion 3 'Quality and Efficiency of the Implementation'
- Applicants will need to provide a breakdown of costs (and not only the overall amount, as previously the case), by filling in the budget table in Part A of the proposal

## Budget for the proposal

| Participant | Country | (A)<br>Direct<br>personnel<br>costs/€ | (B)<br>Other direct<br>costs/€ | (C)<br>Direct costs of<br>sub-<br>contracting/€ | (D)<br>Direct costs of<br>providing<br>financial<br>support to<br>third parties/€ | (E)<br>Costs of inkind<br>contributions<br>not used on the<br>beneficiary's<br>premises/€ | (F)<br>Indirect Costs<br>/ €<br>(=0.25(A+B-E)) | (G)<br>Special unit<br>costs covering<br>direct &<br>indirect costs<br>/ € | (H)<br>Total<br>estimated<br>eligible costs<br>/ €<br>(=A+B+C+D+F<br>+G) | (I)<br>Reimburse-<br>ment rate (%) | (J)<br>Max.EU<br>Contribution /<br>€<br>(=H*I) | (K)<br>Requested<br>EU<br>Contribution/<br>€ |
|-------------|---------|---------------------------------------|--------------------------------|---|---|---|--|--|--|------------------------------------|--|--|
|             |         | ?                                     | ?                              | ?   | ?   | ?   | ?  | ?  | ?  | ?                                  | ?  |  |
|             |         | 0                                     | 0                              | 0   | 0   | 0   | 0,00   | 0  | 0,00   | 100                                | 0,00   |  |
| Total       |         | 0                                     | 0                              | 0   | 0   | 0   | 0,00   | 0  | 0,00   |                                    | 0,00   |  |

# Call 23

Applicants must use the electronic submission service which is under the **Funding and Tenders Portal**:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

- To access the portal and submit a proposal, applicants must have:
  - An **EU Login account** (previously, 'ECAS' account)
  - Their **organisation registered** on the Participant Portal Beneficiary Register, with a 9-digit **Participant Identification Code (PIC) number**

If you do not have an EU Login account yet, you can create an EU Login account on the Funding and Tenders Portal , and register your organisation.

More information: [http://ec.europa.eu/research/participants/docs/h2020-funding-guide/user-account-and-roles/ecas-login\\_en.htm](http://ec.europa.eu/research/participants/docs/h2020-funding-guide/user-account-and-roles/ecas-login_en.htm)



# Participation rules

# A single set of rules



EU Financial  
Regulation  
Specific rules  
for  
participation

- Covering all H2020 research and innovation actions
- Adaptability where needed:
  - Entities eligible for funding
  - IP

# Conditions for Call 23 two-stages

H2020 Rules for participation apply to IMI2 JU Call for Proposals and Actions except where specifically derogated

- **Minimum conditions**

- RIA: at least three independent legal entities, each established in a different EU Member State or H2020 associated country

- **Two-stages**

- Stage 1 SPs from applicants requesting JU funding (30 page limit)

- Stage 2 merging 1<sup>st</sup>ranked SPs with industry consortia (70 page limit)

- **Evaluation criteria**

- At stage 1, all 3 criteria are evaluated (including budget)

- Evaluation criteria, thresholds and Proposal templates have been revised as of Call 18

- Threshold is 3 for each of the evaluation criteria 'excellence', 'impact' and 'quality and efficiency of the implementation'
    - the overall threshold is 10

# Conditions for Call 23 two-stages

- **Submission tool**

SPs/FPs to be submitted through the Electronic Submission Service under the Funding and Tenders Portal

- **Submission deadlines**

Established in the Call topic text both for stage 1 and 2

- **Indicative contribution**

For each topic, the maximum JU contribution and the estimated industry contributions are set in the call text

- **Hearings**

If necessary, at stage 1 hearings might be organised with applicants during panel meetings. After submission deadline, coordinators will be informed about the possible date for the hearing (👉 **check SP details!**)

# Conditions for Call 23 two-stages

- **Information on the outcome of the evaluation:**

Information to the applicants - max 5 months from submission deadline

N.B. GA signature is expected by Q3 2021, specific timelines will be provided after stage 2.

- **Financial Support to Third Parties**

Where relevant, applicants should develop in FPs open, transparent, objective processes and criteria for the allocation of financial support in accordance to Annex K of the H2020 WP and article 15 of the IMI2 JU MGA

- **Plan for exploitation and dissemination**

It must be included in 2<sup>nd</sup> stage Full proposals

**NB:** Contacts/discussions about a given topic between potential applicant consortia and members of the industry consortium are prohibited throughout the procedure until the results of the first stage evaluation.

# Attracting stakeholders

**Any legal entity, regardless its place of establishment, carrying out work relevant to the Call objectives may be part of applicant consortia**

**But... not all participating entities are eligible for funding**

# Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises ( $\leq$  €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- **EU Member State**
- **Associated Country**

***Other countries:***

*No funding **unless participation deemed essential** by IMI2 JU for carrying out the action*

Art.1 Commission Delegated Regulation (EU) No 622/2014

# Expected consortia – Call 23

## *Stage 1 of two stage - Short Proposals*

- **Consortia consisting of:**
  - IMI2 JU fundable legal entities carrying out activities relevant for achieving the project objectives
  - additional legal entities carrying out activities relevant for achieving the project objectives.

# Expected consortia Call 23

## *Stage 2 of two stage – Full Proposals*

- **One Full Consortium per topic consisting of:**
  - 1<sup>st</sup> ranked SP consortium - IMI2 JU fundable legal entities/additional legal entities
  - Industry consortium (EFPIA companies and IMI2 JU Associated Partners) associated to the relevant topics



# Funding rules

# IMI2 JU Funding model

- **IMI2 JU is a PPP, actions are normally co-funded by:**
  - JU funding to BRFs (**B**eneficiaries **R**eceiving **F**unding = legal entities eligible for funding)
  - In-kind/cash contribution from BNRFs (**B**eneficiaries **N**ot **R**eceiving **F**unding):
    - EFPIA constituents and affiliates
    - IMI2 JU Associated Partner

Other legal entities may also participate as BNRFs at their own cost

# One single funding rate per project - BRFs

**One project = One rate**

**For all beneficiaries and all activities**

- 100% of the direct eligible costs
- Indirect costs: **25% flat rate**

# JU contribution to BRFs covers:

- **Personnel**

- Wider acceptance of average personnel costs
- Acceptance of supplementary payments  
For non-profit organisations of up to 8000 euros/year/person
- Less requirements for time records

- **Equipment, consumables, travels...**

- **Subcontracting**

Considering BRFs accounting and management principles

- **BRFs (only) may also receive Financial contribution from EFPIA/APs**

- to be reported as receipts

# IMI2 JU GA: third parties

Third party is a *legal entity which carries out work of the action, supplies goods or provide services for the action, but which did not sign the grant agreement*

## Types of third parties:

1. Third parties directly carrying out part of the work described in Annex 1 of the GA
2. Other third parties: providing resources, goods or services to beneficiaries carrying out the work described in Annex 1
3. Third parties receiving financial support (money) from the beneficiary as part of the action, subject to specific conditions, i.e. Annex K H2020 WP

# Overview different types of third parties in GA

| TYPE  | CHARACTERISTICS  |  |                         |                               |                 |   |                    |
|---|--|--|-------------------------|-------------------------------|-----------------|---|--------------------|
|   | Works on action tasks?                                     | Provides resources or services for action? | What is eligible?       | Must be indicated in Annex 1? | Indirect costs? | Selecting the third party   | GA articles        |
| Linked third party                                      | YES  | NO   | Costs                   | YES                           | YES             | Must be affiliated or have a legal link and be eligible for funding | Article 14         |
| International partners                                  | YES  | NO   | N/A                     | YES                           | N/A             | Must not be eligible for funding                                    | Article 14a        |
| Subcontractor   | YES  | NO   | Price                   | YES                           | NO              | Must be best value for money, avoid conflict of interest            | Article 13         |
| Third party providing in-kind contribution              | NO   | YES  | Costs                   | YES                           | YES             | May not be used to circumvent the rules                             | Articles 11 and 12 |
| Contractor (selling, equipment, good or service)        | NO   | YES  | Price                   | NO                            | YES             | Must be best value for money, avoid conflict of interest            | Article 10         |
| Third parties receiving financial support <sup>31</sup> | The third parties participate in the action as recipients. |  | Amount of support given | YES                           | NO              | According to the conditions in Annex 1                              | Article 15         |

# EFPIA and Associated Partners contribution - BNRFs

- EFPIA companies
- Other industries and partners (= Associated Partners to IMI2)
  - In-kind (actual direct and indirect costs or average FTE) and/or financial contributions (FC)\*
  - Based on the usual management principles and accounting practices
  - Contributions from affiliated entities as part of in-kind

\* Recipient of FC must be BRFs, i.e. eligible for JU funding

When relevant to IMI2 JU objectives: non-EU in-kind contribution (up to 30% at programme level)

Annual financial reporting is disconnected from GA periodic reports

# Deadlines for reporting

- Scientific reporting (full consortium) due at project deadlines (i.e.GA), duration reporting period: 12 months
- Financial reporting for:
  - Beneficiaries receiving JU funding, due at project deadlines (i.e.GA)
  - CFS: >EUR 325k at project end
  - Beneficiaries Not receiving funding (e.g. EFPIA companies and APs),
  - due by 31 Jan - certification by 30 April - covering previous calendar year


# IMI2 JU's Intellectual Property (IP) rules

# One set of rules for multiple interests

Support to  
industry

Incentive to  
participate

Freedom of  
access



Dissemination  
of information

Compensation  
for IP

# Background vs. Results

## Background

Any data, know-how or information including any rights such as IP:

- 1) held before GA
- 2) needed for action or exploit the results
- 3) identified and agreed

Start

## Implementation of the action

End

### Results

Any output (data, knowledge or information etc) generated in the action, as rights attached to it, including IP

Access rights to Results

Access rights to Background

## Sideground

Any data, know-how or information including any rights such as IP **generated during the action but outside of its objectives** and not needed for implementation or Research Use

=> Importance of Action objectives

# Ownership of results

Results are owned by the beneficiary that generates them

Possible transfer of ownership of Results only after their generation:

- Pre-allocation of ownership **NO**
- Prior agreement on transfer after generation **YES**

# Protection of results

## Mandatory for beneficiaries receiving funding

- lies with the owner(s) in adequate and effective manner based on relevant (national) legal provisions, action peculiarities, type of result and legitimate interests
- Type of protection to be reported to the JU
- if valuable results left unprotected, to be discussed within the consortium and inform JU

# Access Rights

*Articles 25 IMI2 MGA (to background) and 31 IMI2 MGA (to results)*

- Access rights = rights to use
- Mandatory written request
- Access rights are in principle not sub licensable but beneficiaries may agree in the consortium agreement to define certain situations where sublicense apply => **Traceability**
- Time limit to request access rights
  - No minimum/maximum
  - Consistent with particular project/results/background

# Mandatory access rights: right to use

## Background

- Access rights to beneficiaries
- for action implementation (including to affiliated entities)
  - If needed for research use of results

## Results

- Access rights to beneficiaries:
- for action implementation (including to affiliated entities)
  - For research use of results

## Background

- Access rights to third parties:
- after completion of the action
  - if needed for research use of results
  - possibility to exclude certain elements

## Results

- Access rights to third parties:
- after completion of the action
  - within established time limits
  - for research use of results

# Purposes of Access Rights: Research Use vs. Direct Exploitation

## Research Use

- Use of results or background necessary to use the results for all purposes other than for completing the action or for direct exploitation
- The application of results (like an animal model or a biomarker) as a tool for research and clinical research in the discovery or development (as the case may be for commercialisation) of pharmaceutical products by for-profit institutions and organisations

## Direct Exploitation

- Development for commercialisation or to commercialise the results
- Commercialisation of such biomarker itself as a diagnostic kit would be direct exploitation

# Access Rights conditions

| Access rights granted by a beneficiary to/on                          | Background<br>(necessary and identified)                       | Results  | Sideground |
|---|--|--|------------|
| Beneficiaries for completion of the action                            | Royalty-free   | Royalty-free   | N.A.       |
| Beneficiaries and affiliates for Research Use                         | Fair & reasonable conditions<br>(e.g. Royalty-free conditions) | Fair & reasonable conditions<br>(e.g. Royalty-free conditions) | N.A.       |
| Third Parties for Research Use after the action                       | Appropriate conditions   | Appropriate conditions   | N.A.       |
| Beneficiaries and affiliates or Third Parties for Direct Exploitation | To be negotiated   | To be negotiated   | N.A.       |

# Dissemination modalities

Each beneficiary has the obligation to disseminate its own results

As soon as reasonably practicable

For publications: Open access is mandatory

Mandatory to mention IMI support & EFPIA in-kind contribution in patent applications / all communications & dissemination

IMI2 JU Communication guide:

<https://www.imi.europa.eu/apply-funding/call-documents/imi2-call-documents>

# Reference documents


- **H2020 Rules for Participation**
  - IPR section: Article 1.3.c and Articles 41 to 49
- **IMI2 – EC Delegated Regulation**
  - IPR section: Articles 2 to 7
- **IMI2 model Grant Agreement** (revised November 2017)
  - IPR section: Articles 23a to 31
- **IMI2 annotated Grant Agreement**

[www.imi.europa.eu/apply-funding/call-documents/imi2-call-documents](http://www.imi.europa.eu/apply-funding/call-documents/imi2-call-documents)



# From Call to grant award

# IMI2 JU Call 23 two-stages



# A single set of evaluation criteria



- As of Call 18, the evaluation criteria, thresholds and proposal templates have been revised
- Two-stage evaluation: all three criteria considered at both stages
- Thresholds and weighting in the **Call documents** depending two-stages/single stage
- Minimum of **3 independent experts**

Each proposal **evaluated 'as it is'**, not as 'what could be'

# Proposal Template

- Available on IMI website & H2020 submission tool
- For first stage proposals, the page limit is **30 pages**.

**Title of Proposal**

**List of participants**

**Table of Contents**

## **1. EXCELLENCE**

**1.1 Objectives**

**1.2 Concept and methodology**

**1.3 Ambition**

## **2. IMPACT**

**2.1 Expected impacts**

**2.2 Outline Measures to maximise impact**

## **3. IMPLEMENTATION**

**3.1 Outline of project work plan — Work packages, and major deliverables**

**3.2 Management structure and procedures**

**3.3 Consortium as a whole**

**3.4 List of work packages**

## **4. PARTICIPANTS**

**4.1. Participants (applicants)**

# Evaluation Criteria (1/2)

## ■ Excellence

- Level to which all the objectives of the Call topic text are addressed;
- Soundness of the concept and credibility of the proposed methodology;
- Extent that the proposed work is beyond the state of the art and demonstrates innovation potential;
- Appropriate consideration of interdisciplinary approaches and use of stakeholder knowledge.

## ■ Impact

- Demonstration of how the outputs of the project will contribute to each of the expected impacts mentioned in the relevant Call topic text;
- Outline of how the project plans to leverage the public-private partnership model to achieve greater impact on innovation within research and development, regulatory, clinical and healthcare practices, as relevant ;
- Impacts on competitiveness and growth of companies including SMEs;
- Quality of the proposed outline to:
  - Disseminate, exploit and sustain the project results;
  - Manage research data;
  - Communicate the project activities to relevant target audiences.

# Evaluation Criteria (2/2)

## ■ Quality and efficiency of the implementation

- Quality and effectiveness of the work plan outline, including extent to which the resources assigned to work packages are in line with their objectives and deliverables;
- Appropriateness of the outline management structures and procedures;
- Appropriateness of the allocation of tasks, ensuring that all participants have a valid role and adequate resources in the project to fulfil that role;
- Complementarity of the participants and extent to which the consortium as whole brings together the necessary expertise;
- Strategy to create a successful partnership with the industry consortium as mentioned in the Call topic text.

- 3 for each of the evaluation criteria 'excellence', 'impact' and 'quality and efficiency of the implementation'
- the overall threshold is 10

# Keeping the momentum

**Maximum Time To Grant: 8 months** from submission of full proposal:

**N.B. Call 23 GAs expected to be signed by end of Q3 2021**

**5 months**  
for informing applicants  
of scientific evaluation

**3 months**  
for signature of grant  
agreement

***NEW*** Legal entity validated in parallel

# IMI2 JU Grant Agreement



- The new IMI2 JU MGA (v.5) will apply to Call 23
- It follows H2020 Model Grant Agreement (v.5) with IMI2 specificities.
- IMI2 JU Annotated Model Grant Agreement v.2.2 (based upon H2020 AGA v.5.2)
- It is e-signed between IMI2 JU and Coordinator only. Other beneficiaries e-sign Accession Forms
- EFPIA and Associated Partners are beneficiaries not receiving funding (BNRFs, Art.9) - their financial report occurs outside the GA, for more info please consult '*IMI2 JU guidelines for reporting in kind and financial contributions by Members other than the Union and Associated Partners*'

# IMI2 Grant Agreement

Article 41.3 - Consortium agreement *may cover*:

- *internal organisation of the consortium, including allocation of scientific tasks among beneficiaries*



## Scientific Project Leadership

Scientific Project Leader may be different from Coordinator to:

- reflect the spirit of industrial co-leadership in call topics built upon EFPIA/industry scientific priorities
- address the need for strong scientific coordination and collaboration between BRFs (JU funded) and BNRFs (industry)



IMI2 specificities are presented in the IMI2 JU AGA

# Consortium agreement

- Contractual arrangement **between all participants** to set out their rights and obligations, especially governance, liability and IPR
- Shall comply with the **IMI2 JU Model Grant Agreement**
- To be agreed before the signature of the GA, IMI2 JU is not a party
- **To be adapted to the specific needs of each IMI action!**
- A template prepared by EFPIA shows what a consortium agreement might look like:

<http://efpia.eu/documents/229/141/EFPIA-Consortium-Agreement-Template-for-IMI2-actions>

Consortia may also use alternative templates if they wish.



## Tips for success

# Common Mistakes

- **Admissibility/Eligibility criteria not met:**
  - Submission **deadline** missed
  - Proposal **out of scope**  
(if you have doubts on how to respond to the Call contact us)
  - Not involving at least **three independent legal entities** (RIA) from **three** different **MS/AC**

# Common Mistakes

- The proposal does not address all the **objectives** (in some cases proposals have nothing to do with the topic!)
- Submitted text does not respect the proposal template (sometimes received even slides!)
- Ensure to follow the instructions of the proposal template
- Applicants do not have the **capabilities** to address all of the objectives or there is redundancy between partners
- A proposal is scientifically excellent but will have **limited impact**
- **Budget**, either over-estimated or not fully justified
- **Ethical issues** not addressed

# Tips

- **Read all the Call-relevant material that is provided on the IMI website – [www.imi.europa.eu](http://www.imi.europa.eu)**
- **Understand IMI2 JU rules** and respect them
- **Consider the PPP dimension** of the action (e.g. Governance, industry contribution vs IMI2 JU funding)
- **If in doubt, ask** a member of the Programme Office
- Your proposal should provide **reviewers** with all the information requested to allow them to evaluate it
- Start **working early** (pre-materials available before)
- Dedicate sufficient time to submit the proposal: create an EU login account, obtain a PIC number - **don't wait until the last day to start the submission process**
- **More tips:** [www.imi.europa.eu/content/tips-applicants](http://www.imi.europa.eu/content/tips-applicants)

# Submitting a proposal

Via the **new** Funding and Tenders Portal

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

The screenshot shows the 'Funding & tender opportunities' portal. At the top, there is a header with the European Commission logo and the text 'Funding & tender opportunities Single Electronic Data Interchange Area (SEDIA)'. On the right, there are links for 'English EN', 'Register', and 'Login'. Below the header is a navigation bar with a home icon and menu items: 'SEARCH FUNDING & TENDERS', 'HOW TO PARTICIPATE', 'PROJECTS & RESULTS', 'WORK AS AN EXPERT', and 'SUPPORT'. A 'select programme' button is also present.

The main content area features a blue banner with the text: 'The Funding & Tenders Portal is the entry point (the Single Electronic Data Interchange Area) for participants and experts in funding programmes and tenders managed by the European Commission and other EU bodies.' A 'Feedback' button is on the right side of this banner.

Below the banner is a section titled 'Find calls for proposals and tenders' with a search bar containing the placeholder text 'Search calls for proposals and tenders by keywords, programmes...' and a yellow 'Search' button.

The bottom section is titled 'Calls for proposals by EU Programme' and contains a grid of 14 programmes. The 'Horizon 2020 Framework Programme (H2020)' is circled in red.

|  |   |                          |   |                                      |   |                                       |   |
|--|---|--------------------------|---|--------------------------------------|---|---------------------------------------|---|
| 3rd Health Programme (3HP)                     | Asylum, Migration and Integration Fund (AMIF) | Consumer Programme (CP)  | Creative Europe (CREA)                        | Erasmus+ Programme (EPLUS)           | European Maritime and Fisheries Fund (EMFF) | HERCULE III (HERC)                    | <b>Horizon 2020 Framework Programme (H2020)</b> |
| Internal Security Fund Borders and Visa (ISFB) | Internal Security Fund Police (ISFP)          | Justice Programme (JUST) | Pilot Projects and Preparatory Actions (PPPA) | Programme for the Competitiveness of | Promotion of Agricultural Products (AGRIP)  | Research Fund for Coal & Steel (RFCS) | Rights, Equality and Citizenship Programme      |

# Submitting a proposal

Look for IMI2 JU Calls, you will find the links to start the submission of a proposal:

The screenshot displays the European Commission's 'Funding & tender opportunities' portal. The search results are filtered for 'IMI2' grants. The results list three grants, each with details on the types of action, opening dates, and deadlines.

**Search Results:**

- Grant: Optimising future obesity treatment IMI2-2019-17-01**  
Types of action: Research and Innovation action | Programme: Horizon 2020  
Open for submission: 22 January 2019  
Deadline model: two-stage  
Deadline date: 25 April 2019 17:00:00 Brussels time  
Second stage deadline: [dropdown]
- Grant: Open access chemogenomics library and chemical probes for the druggable genome IMI2-2019-17-02**  
Types of action: Research and Innovation action | Programme: Horizon 2020  
Open for submission: 22 January 2019  
Deadline model: two-stage  
Deadline date: 25 April 2019 17:00:00 Brussels time  
Second stage deadline: [dropdown]
- Grant: Intelligent prediction and identification of environmental risks posed by human medicinal products IMI2-2019-17-03**  
Types of action: Research and Innovation action | Programme: Horizon 2020  
Open for submission: 22 January 2019  
Deadline model: two-stage  
Deadline date: 25 April 2019 17:00:00 Brussels time  
Second stage deadline: [dropdown]

# Proposal Submission Form - Part A

*Please indicate only one of the following options if applicable to your organisation*

Companies (including micro enterprises and SMEs) with an annual turnover up to EUR 500 millions which are not affiliated entities of companies with an annual turnover of more than EUR 500 millions

Patients Organisation

Regulatory Agency

Member of EFPIA not requesting funding

IMI2 Associated Partners to this topic not requesting funding

Any other organisation not requesting funding

*Certain type of organisations are not covered by the above options, in that case none should be selected*

- Where applicable, the organisation type has to be indicated (see above):
  - Applies to the 6 types of organisations identified in the form;
  - If none of the options is selected, the system generates a warning;
  - The warning is not blocking the submission of the proposal.

# Proposal Submission Form - Part A

## Validation result

**Show Error** The red 'Show Error' button indicates an error due to a missing or incorrect value related to the call eligibility criteria. The submission of the proposal **will be blocked** unless that specific field is corrected!

**Show Warning** The yellow 'Show Warning' button indicates a warning due to a missing or incorrect value related to the call eligibility criteria. The submission of the proposal **will not be blocked** (proposal will be submitted with the missing or incorrect value).

| Section      | Description   |              |
|--------------|---|--------------|
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Legal Entity | Please indicate if your organisation is one of the following legal entity.                      | Show Warning |
| Budget       | The indirect cost (F) for the project is zero. Please check the budget columns (A),(B) and (E). | Show Warning |
| Budget       | The requested EU Contribution (K) value cannot be zero.   | Show Warning |

- When validating the forms, different warnings appear (see above):
  - The yellow warnings don't block the submission of the proposal;
  - Only the warnings flagged in red will block the submission of the proposal.

# Proposal Submission Form - Part A

## 4 - Call specific questions

*Essential information to be provided for proposals including clinical Trials / studies / investigations*

**Applies to proposals including clinical trials / studies / investigations**

|   |                                      |                          |
|---|--------------------------------------|--------------------------|
| Are clinical studies / trials / investigations included in the work plan of this project? | <input checked="" type="radio"/> Yes | <input type="radio"/> No |
|---|--------------------------------------|--------------------------|

Please upload the dedicated annex 'Essential information for clinical studies / trials / investigations' (a Word template is provided under 'download templates' in the up-load section for Part B and Annexes).

This document should include the relevant information of each clinical study / trial / investigation included in the work plan of this project.

|   |  |
|---|--|
| Please give a short title, an acronym or a unique identifier to each clinical study / trial / investigation, <u>to be used as a reference/ identifier in the other parts of the proposal.</u> |  |
| <i>Give short title/acronym/unique identifier</i>   |  |

- If the proposal includes clinical trials/studies/investigations, in stage one of two-stages calls, the specific annex is not requested (see above the section):
  - In stage one relevant aspects should be integrated in part B of the proposal template;
  - The dedicated annex is compulsory in stage two (see *Clinical trial template*).

# Tips for writing a successful proposal

- Read **all the call-relevant material**:  
[www.imi.europa.eu](http://www.imi.europa.eu)
- Begin forming your consortium **early**  
Partner search tools & networking events
- Provide **reviewers** with all the information requested to allow them to evaluate your proposal
- **Finalise and submit your proposal early**
- Contact the **IMI Office** (**NOT** industry topic writers):  
[infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)

# Find project partners

- Network with **your contacts**
- **Network** with fellow webinar participants
- Use **Partner Search Tools**:
  - EU Funding & Tenders portal: <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search>
  - German NCP partner search tool: [www.imi-partnering.eu](http://www.imi-partnering.eu)
- Get in touch with your **local IMI contact point**:  
[www.imi.europa.eu/about-imi/governance/states-representatives-group](http://www.imi.europa.eu/about-imi/governance/states-representatives-group)
- Talk to your **Health National Contact Point (NCP)**
- Network on **social media** (e.g. IMI LinkedIn group)



**More information**

# Stay in touch

- Visit our new website [www.imi.europa.eu](http://www.imi.europa.eu)
- Sign up to our newsletter [via the website](#)
- Follow us on Twitter [@IMI\\_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group [bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)
- E-mail us [infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)



The screenshot shows the IMI website homepage. At the top left is the IMI logo and the text 'innovative medicines initiative'. To the right is the tagline 'Europe's partnership for health'. Below this is a navigation bar with links: Home, About IMI, Get involved, Apply for funding, Projects & results, News & events, and Reference documents. The main content area features a large image of a petri dish with colorful bacterial colonies. A text box overlaid on the image reads: 'We are an EU public-private partnership funding health research and innovation'. At the bottom, a statistics bar displays: €5.3bn BUDGET, 90 PROJECTS, 864 PARTICIPANTS, 6 995 PROJECT OUTPUTS, and 2 686 PUBLICATIONS.

The screenshot shows the Twitter profile for IMI (@IMI\_JU). The profile header includes the IMI logo, the name 'innovative medicines initiative', and the hashtag #InvestEUresearch. The profile statistics are: Tweets 5,476, Following 2,229, Followers 6,393, Likes 751, Lists 3, and Moments 0. The bio states: 'The Innovative Medicines Initiative (IMI) is a public-private partnership aiming to speed up the development of better and safer medicines for patients.' The location is Brussels, the website is imi.europa.eu, and it was joined in June 2010. There are 571 photos and videos. The main content shows a pinned tweet from October 24, 2023, by Commissioner @Moedas about the Sierra Leone Ebola vaccine trial. Below the tweet is a photo of Commissioner Moedas and IMI staff at a booth. Another tweet from 38 minutes ago mentions the BIOEUROPE event in Berlin.

# Your contact points

## At the IMI Programme Office

- General queries: [applicants@imi.europa.eu](mailto:applicants@imi.europa.eu)
- IP queries: [IMI-IP-Helpdesk@imi.europa.eu](mailto:IMI-IP-Helpdesk@imi.europa.eu)

## Local contacts

- IMI2 JU States Representatives Group: [bit.ly/IMISRG](http://bit.ly/IMISRG)
- Horizon 2020 Health National Contact Points: [bit.ly/H2020\\_NCPs](http://bit.ly/H2020_NCPs)



# Questions



**Thank you**

